MSSA and MRSA Screening in Patients Undergoing Elective TJA: the Benefits of Next-generation Sequencing
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Rothman Orthopaedic Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients undergoing primary total knee or total hip arthroplasty at our institution will be eligible.
Exclusion Criteria:
- Patients included in other prospective studies
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic techniques to identify S. aureus in total joint replacement patients
Time Frame: 1 day
|
to model the potential effect of different diagnostic techniques on S. aureus detection in orthopaedic patients.
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- JPARV20D.165
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcus Aureus
-
NCT06290557Recruiting
-
NCT03685487Completed
-
NCT04884958Unknown
-
NCT07155590Active, not recruitingStaphylococcal Aureus Infection | Staphylococcus Aureus Bacteraemia
-
NCT03455309CompletedStaphylococcus Aureus
-
NCT07612813Not yet recruitingStaphylococcus Aureus Bloodstream Infection
-
NCT07148960Enrolling by invitationStaphylococcus Aureus Bacteremia
-
NCT06650501RecruitingStaphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septicemia | S. Aureus Bacteremia | S. Aureus Bloodstream Infection | Staphylococcus Aureus Bloodstream Infection
-
NCT07376889Not yet recruitingStaphylococcus Aureus Bacteremia
-
NCT06637332RecruitingStaphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septicemia | S. Aureus Bacteremia | S. Aureus Bloodstream Infection
Clinical Trials on next generation sequencing
-
NCT04110769RecruitingPancreatic Cancer | Chemotherapy Effect | Genetic Change
-
NCT05627505Not yet recruiting
-
NCT04122833RecruitingAdenocarcinoma of Lung | EGFR Activating Mutation
-
NCT07403916Active, not recruitingInfluence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric CancerMolecular Analysis | Next-generation Sequencing | Gastric Cancer (GC)
-
NCT03066310CompletedBladder Cancer | Urine | Diagnosis | Biomarker
-
NCT03356249CompletedSepsis | Septic Shock
-
NCT03232242UnknownInfectious Disease | Next Generation Sequencing
-
NCT05783973RecruitingThis Study Aims to Reveal the Effectiveness, Accuracy, and Feasibility in Bile
-
NCT05183906Recruiting